PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

EU clears Roche’s Polivy for certain lymphomas

The European Commission has approved Roche’s Polivy (polatuzumab vedotin) for people with previously treated aggressive lymphoma.

The Commission’s marketing authorisation is for the drug in combination with bendamustine plus MabThera (rituximab), for the treatment of adult patients who have relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and are not candidates for a haematopoietic stem cell transplant.

On the news of the approval, “people in the EU with relapsed or refractory diffuse large B-cell lymphoma will have the opportunity to benefit from this new Polivy combination,” said Levi Garraway, Roche’s chief medical officer and head of global product development.

He reminded, “For patients battling this aggressive disease, the prognosis is poor and few treatments are available. We are proud to bring this first-in-class treatment option to those who need it most.”

Roche revealed that the conditional approval is based on the results from the phase Ib/II GO29365 study, the first and only clinical trial to show higher response rates and improved overall survival (OS) compared to MabThera in the indication.

Data revealed that 40% of people treated with Polivy plus MabThera achieved a complete response, and as such no cancer could be detected at the time of assessment, compared to 17.5 with just MabThera alone.

Roche reminds that the EU approval follows the US Food and Drug Administration’s (FDA) accelerated approval of the combo in June last year.

DLBCL is the most common form of non-Hodgkin lymphoma (NHL), accounting for about one in three cases.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026